Can the status of the breast and ovarian cancer susceptibility gene 1 product (BRCA1) predict response to taxane-based cancer therapy?

Anti-Cancer Agents in Medicinal Chemistry

Volumn 9, Issue 5, 2009, Pages 543-549

  DeLigio, J Thomas ^a,d   Velkova, Aneliya ^b,c   Zorio, Diego A R ^a   Monteiro, Alvaro N A ^b  

^a Taxolog Inc   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

^d FLORIDA STATE UNIVERSITY   (United States)

Author keywords

Biomarker; BRCA1; Cancer; Chemotherapy; Microtubule; Taxane; Taxol; Tubulin

Indexed keywords

AURORA KINASE INHIBITOR; BRCA1 PROTEIN; CARBOPLATIN; CHECKPOINT KINASE 1; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUOROURACIL; GEMCITABINE; NAVELBINE; PACLITAXEL;

APOPTOSIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CELL CYCLE ARREST; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DISEASE MARKER; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESPONSE; DRUG SENSITIVITY; DRUG STRUCTURE; DRUG TARGETING; GENE EXPRESSION REGULATION; GENE FUNCTION; GENETIC SUSCEPTIBILITY; HEAD AND NECK CARCINOMA; HUMAN; LUNG NON SMALL CELL CANCER; MICROTUBULE ORGANIZING CENTER; OVARY CANCER; SHORT SURVEY; SIGNAL TRANSDUCTION;

EID: 67651112151     PISSN: 18715206     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152009788451798     Document Type: Short Survey

References (75)

1. Wani, M.C.; Taylor, H.L.; Wall, M.E.; Coggon, P.; McPhail, A.T. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J. Am. Chem. Soc. 1971, 93(9), 2325-2327.
2. Schiff, P.B.; Fant, J.; Horwitz, S.B. Promotion of microtubule assembly in vitro by taxol. Nature 1979, 277(5698), 665-667.
3. Schiff, P.B.; Horwitz, S.B. Taxol stabilizes microtubules in mouse fibroblast cells. Proc. Natl. Acad. Sci. USA 1980, 77(3), 1561-1565.
4. Luduena, R.F. Multiple forms of tubulin: different gene products and covalent modifications. Int. Rev. Cytol. 1998, 178, 207-275.
5. Rao, S.; Krauss, N.E.; Heerding, J.M.; Swindell, C.S.; Ringel, I.; Orr, G.A.; Horwitz, S.B. 3′-(p-azidobenzamido)taxol photolabels the N-terminal 31 amino acids of beta-tubulin. J. Biol. Chem. 1994, 269(5), 3132-3134.
6. Rao, S.; Orr, G.A.; Chaudhary, A.G.; Kingston, D.G.; Horwitz, S.B. Characterization of the taxol binding site on the microtubule. 2-(m-Azidobenzoyl)taxol photolabels a peptide (amino acids 217-231) of beta-tubulin. J. Biol. Chem. 1995, 270(35), 20235-20238.
7. Rao, S.; He, L.; Chakravarty, S.; Ojima, I.; Orr, G.A.; Horwitz, S.B. Characterization of the Taxol binding site on the microtubule. Identification of Arg(282) in beta-tubulin as the site of photoincorporation of a 7-benzophenone analogue of Taxol. J. Biol. Chem. 1999, 274(53), 37990-37994.
8. Nogales, E.; Wolf, S.G.; Downing, K.H. Structure of the alpha beta tubulin dimer by electron crystallography. Nature 1998, 391(6663), 199-203.
9. Giannakakou, P.; Sackett, D.L.; Kang, Y.K.; Zhan, Z.; Buters, J.T.; Fojo, T.; Poruchynsky, M.S. Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. J. Biol. Chem. 1997, 272(27), 17118-17125.
10. Gonzalez-Garay, M.L.; Chang, L.; Blade, K.; Menick, D.R.; Cabral, F.A beta-tubulin leucine cluster involved in microtubule assembly and paclitaxel resistance. J. Biol. Chem. 1999, 274(34), 23875-23882.
11. McGrogan, B.T.; Gilmartin, B.; Carney, D.N.; McCann, A. Taxanes, microtubules and chemoresistant breast cancer. Biochim. Biophys. Acta 2008, 1785(2), 96-132.
12. Henderson, I.C.; Berry, D.A.; Demetri, G.D.; Cirrincione, C.T.; Goldstein, L.J.; Martino, S.; Ingle, J.N.; Cooper, M.R.; Hayes, D.F.; Tkaczuk, K.H.; Fleming, G.; Holland, J.F.; Duggan, D.B.; Carpenter, J.T.; Frei, E., III; Schilsky, R.L.; Wood, W.C.; Muss, H.B.; Norton, L. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J. Clin. Oncol. 2003, 21(6), 976-983.
13. Citron, M.L.; Berry, D.A.; Cirrincione, C.; Hudis, C.; Winer, E.P.; Gradishar, W.J.; Davidson, N.E.; Martino, S.; Livingston, R.; Ingle, J.N.; Perez, E.A.; Carpenter, J.; Hurd, D.; Holland, J.F.; Smith, B.L.; Sartor, C.I.; Leung, E.H.; Abrams, J.; Schilsky, R.L.; Muss, H.B.; Norton, L. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J. Clin. Oncol. 2003, 21(8), 1431-1439.
14. Mamounas, E.P.; Bryant, J.; Lembersky, B.; Fehrenbacher, L.; Sedlacek, S.M.; Fisher, B.; Wickerham, D.L.; Yothers, G.; Soran, A.; Wolmark, N. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J. Clin. Oncol. 2005, 23(16), 3686-3696.
15. Martin, M.; Pienkowski, T.; Mackey, J.; Pawlicki, M.; Guastalla, J.P.; Weaver, C.; Tomiak, E.; Al-Tweigeri, T.; Chap, L.; Juhos, E.; Guevin, R.; Howell, A.; Fornander, T.; Hainsworth, J.; Coleman, R.; Vinholes, J.; Modiano, M.; Pinter, T.; Tang, S.C.; Colwell, B.; Prady, C.; Provencher, L.; Walde, D.; Rodriguez-Lescure, A.; Hugh, J.; Loret, C.; Rupin, M.; Blitz, S.; Jacobs, P.; Murawsky, M.; Riva, A.; Vogel, C. Adjuvant docetaxel for node-positive breast cancer. N. Engl. J. Med. 2005, 352(22), 2302-2313.
16. Bear, H.D.; Anderson, S.; Brown, A.; Smith, R.; Mamounas, E.P.; Fisher, B.; Margolese, R.; Theoret, H.; Soran, A.; Wickerham, D.L.; Wolmark, N. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J. Clin. Oncol. 2003, 21(22), 4165-4174.
17. Smith, I.C.; Heys, S.D.; Hutcheon, A.W.; Miller, I.D.; Payne, S.; Gilbert, F.J.; Ah-See, A.K.; Eremin, O.; Walker, L.G.; Sarkar, T.K.; Eggleton, S.P.; Ogston, K.N. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J. Clin. Oncol. 2002, 20(6), 1456-1466.
18. Hayes, D.F.; Thor, A.D.; Dressler, L.G.; Weaver, D.; Edgerton, S.; Cowan, D.; Broadwater, G.; Goldstein, L.J.; Martino, S.; Ingle, J.N.; Henderson, I.C.; Norton, L.; Winer, E.P.; Hudis, C.A.; Ellis, M.J.; Berry, D.A.; the Cancer and Leukemia Group. HER2 and response to paclitaxel in node-positive breast cancer. N. Engl. J. Med. 2007, 357(15), 1496-1506.
19. Huang, C.H.; Millenson, M.M.; Sherman, E.J.; Borghaei, H.; Mintzer, D.M.; Cohen, R.B.; Staddon, A.P.; Seldomridge, J.; Treat, O.J.; Tuttle, H.; Ruth, K.J.; Langer, C.J. Promising survival in patients with recurrent non-small cell lung cancer treated with docetaxel and gemcitabine in combination as second-line therapy. J. Thorac. Oncol. 2008, 3(9), 1032-1038.
20. Kubota, K.; Kawahara, M.; Ogawara, M.; Nishiwaki, Y.; Komuta, K.; Minato, K.; Fujita, Y.; Teramukai, S.; Fukushima, M.; Furuse, K. Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study. Lancet Oncol. 2008, 9(12), 1135-1142.
21. Barlesi, F. Lung cancer: moving forward with tailored strategies. Lancet Oncol. 2008, 9(12), 1116-1117.
22. Markman, M. Pharmaceutical management of ovarian cancer: current status. Drugs 2008, 68(6), 771-789.
23. Piccart, M.J.; Bertelsen, K.; James, K.; Cassidy, J.; Mangioni, C.; Simonsen, E.; Stuart, G.; Kaye, S.; Vergote, I.; Blom, R.; Grimshaw, R.; Atkinson, R.J.; Swenerton, K.D.; Trope, C.; Nardi, M.; Kaern, J.; Tumolo, S.; Timmers, P.; Roy, J.A.; Lhoas, F.; Lindvall, B.; Bacon, M.; Birt, A.; Andersen, J.E.; Zee, B.; Paul, J.; Baron, B.; Pecorelli, S. Randomized intergroup trial of cisplatinpaclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J. Natl. Cancer Inst. 2000, 92(9), 699-708.
24. Vasey, P.A.; Jayson, G.C.; Gordon, A.; Gabra, H.; Coleman, R.; Atkinson, R.; Parkin, D.; Paul, J.; Hay, A.; Kaye, S.B. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J. Natl. Cancer Inst. 2004, 96(22), 1682-1691.
25. Stordal, B.; Pavlakis, N.; Davey, R.A systematic review of platinum and taxane resistance from bench to clinic: an inverse relationship. Cancer Treat. Rev. 2007, 33(8), 688-703.
26. Schoffski, P.; Catimel, G.; Planting, A.S.; Droz, J.P.; Verweij, J.; Schrijvers, D.; Gras, L.; Schrijvers, A.; Wanders, J.; Hanauske, A.R. Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Results of a phase II study of the EORTC Early Clinical Studies Group. Ann. Oncol. 1999, 10(1), 119-122.
27. Posner, M.R.; Hershock, D.M.; Blajman, C.R.; Mickiewicz, E.; Winquist, E.; Gorbounova, V.; Tjulandin, S.; Shin, D.M.; Cullen, K.; Ervin, T.J.; Murphy, B.A.; Raez, L.E.; Cohen, R.B.; Spaulding, M.; Tishler, R.B.; Roth, B.; Viroglio, R.C.; Venkatesan, V.; Romanov, I.; Agarwala, S.; Harter, K.W.; Dugan, M.; Cmelak, A.; Markoe, A.M.; Read, P.W.; Steinbrenner, L.; Colevas, A.D.; Norris, C.M., Jr.; Haddad, R.I. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N. Engl. J. Med. 2007, 357(17), 1705-1715.
28. Ferlini, C.; Gallo, D.; Scambia, G. New taxanes in development. Expert. Opin. Investig. Drugs 2008, 17(3), 335-347.
29. Mazumdar, A.; Henderson, Y.C.; El-Naggar, A.K.; Sen, S.; Clayman, G.L. Aurora kinase A inhibition and paclitaxel as targeted combination therapy for head and neck squamous cell carcinoma. Head Neck 2008, 31(5), 625-634.
30. Hall, J.M.; Lee, M.K.; Newman, B.; Morrow, J.E.; Anderson, L.A.; Huey, B.; King, M.C. Linkage of early-onset familial breast cancer to chromosome 17q21. Science 1990, 250(4988), 1684-1689.
31. Narod, S.A.; Feunteun, J.; Lynch, H.T.; Watson, P.; Conway, T.; Lynch, J.; Lenoir, G.M. Familial breast-ovarian cancer locus on chromosome 17q12-q23. Lancet 1991, 338(8759), 82-83.
32. Vogelstein, B.; Kinzler, K.W. Has the breast cancer gene been found? Cell 1994, 79(1), 1-3.
33. Miki, Y.; Swensen, J.; Shattuck-Eidens, D.; Futreal, P.A.; Harshman, K.; Tavtigian, S.; Liu, Q.; Cochran, C.; Bennett, L.M.; Ding, W.A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994, 266(5182), 66-71.
34. Futreal, P.A.; Liu, Q.; Shattuck-Eidens, D.; Cochran, C.; Harshman, K.; Tavtigian, S.; Bennett, L.M.; Haugen-Strano, A.; Swensen, J.; Miki, Y. BRCA1 mutations in primary breast and ovarian carcinomas. Science 1994, 266(5182), 120-122.
35. Wilson, C.A.; Ramos, L.; Villasenor, M.R.; Anders, K.H.; Press, M.F.; Clarke, K.; Karlan, B.; Chen, J.J.; Scully, R.; Livingston, D.; Zuch, R.H.; Kanter, M.H.; Cohen, S.; Calzone, F.J.; Slamon, D.J. Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas. Nat. Genet. 1999, 21(2), 236-240.
36. Narod, S.A.; Foulkes, W.D. BRCA1 and BRCA2: 1994 and beyond. Nat. Rev. Cancer 2004, 4(9), 665-676.
37. Scully, R.; Livingston, D. In search of the tumour-suppressor functions of BRCA1 and BRCA2. Nature 2000, 408, 429-432.
38. Venkitaraman, A.R. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 2002, 108(2), 171-182.
39. Scully, R.; Xie, A.; Nagaraju, G. Molecular functions of BRCA1 in the DNA damage response. Cancer Biol. Ther. 2004, 3(6), 521-527.
40. Lane, T.F. BRCA1 and transcription. Cancer Biol. Ther. 2004, 3(6), 528-533.
41. Kennedy, R.D.; Quinn, J.E.; Mullan, P.B.; Johnston, P.G.; Harkin, D.P. The role of BRCA1 in the cellular response to chemotherapy. J. Natl. Cancer Inst. 2004, 96(22), 1659-1668.
42. Quinn, J.E.; Kennedy, R.D.; Mullan, P.B.; Gilmore, P.M.; Carty, M.; Johnston, P.G.; Harkin, D.P. BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res. 2003, 63(19), 6221-6228.
43. Gilmore, P.M.; McCabe, N.; Quinn, J.E.; Kennedy, R.D.; Gorski, J.J.; Andrews, H.N.; McWilliams, S.; Carty, M.; Mullan, P.B.; Duprex, W.P.; Liu, E.T.; Johnston, P.G.; Harkin, D.P. BRCA1 interacts with and is required for paclitaxel-induced activation of mitogen-activated protein kinase kinase kinase 3. Cancer Res. 2004, 64(12), 4148-4154.
44. Mullan, P.B.; Quinn, J.E.; Gilmore, P.M.; McWilliams, S.; Andrews, H.; Gervin, C.; McCabe, N.; McKenna, S.; White, P.; Song, Y.H.; Maheswaran, S.; Liu, E.; Haber, D.A.; Johnston, P.G.; Harkin, D.P. BRCA1 and GADD45 mediated G2/M cell cycle arrest in response to antimicrotubule agents. Oncogene 2001, 20(43), 6123-6131.
45. Tassone, P.; Tagliaferri, P.; Perricelli, A.; Blotta, S.; Quaresima, B.; Martelli, M.L.; Goel, A.; Barbieri, V.; Costanzo, F.; Boland, C.R.; Venuta, S. BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells. Br. J. Cancer 2003, 88(8), 1285-1291.
46. Chabalier, C.; Lamare, C.; Racca, C.; Privat, M.; Valette, A.; Larminat, F. BRCA1 downregulation leads to premature inactivation of spindle checkpoint and confers paclitaxel resistance. Cell Cycle 2006, 5(9), 1001-1007.
47. Lafarge, S.; Sylvain, V.; Ferrara, M.; Bignon, Y.J. Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway. Oncogene 2001, 20(45), 6597-6606.
48. Zhou, C.; Smith, J.L.; Liu, J. Role of BRCA1 in cellular resistance to paclitaxel and ionizing radiation in an ovarian cancer cell line carrying a defective BRCA1. Oncogene 2003, 22(16), 2396-2404.
49. Trenz, K.; Lugowski, S.; Jahrsdorfer, U.; Jainta, S.; Vogel, W.; Speit, G. Enhanced sensitivity of peripheral blood lymphocytes from women carrying a BRCA1 mutation towards the mutagenic effects of various cytostatics. Mutat. Res. 2003, 544(2-3), 279-288.
50. Rottenberg, S.; Nygren, A.O. H.; Pajic, M.; van Leeuwen, F.W. B.; van der Heijden, I.; van de Wetering, K.; Liu, X.; de Visser, K.E.; Gilhuijs, K.G.; van Tellingen, O.; Schouten, J.P.; Jonkers, J.; Borst, P. Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer. Proc. Natl. Acad. Sci. USA 2007, 0702955104.
51. Orsulic, S.; Li, Y.; Soslow, R.A.; Vitale-Cross, L.A.; Gutkind, J.S.; Varmus, H.E. Induction of ovarian cancer by defined multiple genetic changes in a mouse model system. Cancer Cell 2002, 1(1), 53-62.
52. Xing, D.; Orsulic, S.A Mouse model for the molecular characterization of brca1-associated ovarian carcinoma. Cancer Res. 2006, 66(18), 8949-8953.
53. Thangaraju, M.; Kaufmann, S.H.; Couch, F.J. BRCA1 facilitates stress-induced apoptosis in breast and ovarian cancer cell lines. J. Biol. Chem. 2000, 275(43), 33487-33496.
54. Wassmann, K.; Benezra, R. Mitotic checkpoints: from yeast to cancer. Curr. Opin. Genet. Dev. 2001, 11(1), 83-90.
55. Wang, R.H.; Yu, H.; Deng, C.X. A requirement for breast-cancer-associated gene 1(BRCA1) in the spindle checkpoint. Proc. Natl. Acad. Sci. USA 2004, 101(49), 17108-17113.
56. Joukov, V.; Groen, A.C.; Prokhorova, T.; Gerson, R.; White, E.; Rodriguez, A.; Walter, J.C.; Livingston, D.M. The BRCA1/BARD1 heterodimer modulates ran-dependent mitotic spindle assembly. Cell 2006, 127(3), 539-552.
57. Sudo, T.; Nitta, M.; Saya, H.; Ueno, N.T. Dependence of paclitaxel sensitivity on a functional spindle assembly checkpoint. Cancer Res. 2004, 64(7), 2502-2508.
58. Anand, S.; Penrhyn-Lowe, S.; Venkitaraman, A.R. AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol. Cancer Cell 2003, 3(1), 51-62.
59. Weaver, B.A.; Cleveland, D.W. Decoding the links between mitosis, cancer, and chemotherapy: The mitotic checkpoint, adaptation, and cell death. Cancer Cell 2005, 8(1), 7-12.
60. Pujana, M.A.; Han, J.D.; Starita, L.M.; Stevens, K.N.; Tewari, M.; Ahn, J.S.; Rennert, G.; Moreno, V.; Kirchhoff, T.; Gold, B.; Assmann, V.; Elshamy, W.M.; Rual, J.F.; Levine, D.; Rozek, L.S.; Gelman, R.S.; Gunsalus, K.C.; Greenberg, R.A.; Sobhian, B.; Bertin, N.; Venkatesan, K.; yivi-Guedehoussou, N.; Sole, X.; Hernandez, P.; Lazaro, C.; Nathanson, K.L.; Weber, B.L.; Cusick, M.E.; Hill, D.E.; Offit, K.; Livingston, D.M.; Gruber, S.B.; Parvin, J.D.; Vidal, M. Network modeling links breast cancer susceptibility and centrosome dysfunction. Nat. Genet. 2007, 39(11), 1338-1349.
61. Hsu, L.C.; White, R.L. BRCA1 is associated with the centrosome during mitosis. Proc. Natl. Acad. Sci. USA 1998, 95(22), 12983-12988.
62. Hsu, L.C.; Doan, T.P.; White, R.L. Identification of a gamma-tubulin-binding domain in BRCA1. Cancer Res. 2001, 61(21), 7713-7718.
63. Starita, L.M.; Machida, Y.; Sankaran, S.; Elias, J.E.; Griffin, K.; Schlegel, B.P.; Gygi, S.P.; Parvin, J.D. BRCA1-dependent ubiquitination of gamma-tubulin regulates centrosome number. Mol. Cell Biol. 2004, 24(19), 8457-8466.
64. Sankaran, S.; Starita, L.M.; Groen, A.C.; Ko, M.J.; Parvin, J.D. Centrosomal microtubule nucleation activity is inhibited by BRCA1-dependent ubiquitination. Mol. Cell. Biol. 2005, 25(19), 8656-8668.
65. Kurebayashi, J.; Yamamoto, Y.; Kurosumi, M.; Okubo, S.; Nomura, T.; Tanaka, K.; Sonoo, H. Loss of BRCA1 expression may predict shorter time-to-progression in metastatic breast cancer patients treated with taxanes. Anticancer Res. 2006, 26(1B), 695-701.
66. Kim, S.J.; Miyoshi, Y.; Taguchi, T.; Tamaki, Y.; Nakamura, H.; Yodoi, J.; Kato, K.; Noguchi, S. High thioredoxin expression is associated with resistance to docetaxel in primary breast cancer. Clin. Cancer Res. 2005, 11(23), 8425-8430.
67. Byrski, T.; Gronwald, J.; Huzarski, T.; Grzybowska, E.; Budryk, M.; Stawicka, M.; Mierzwa, T.; Szwiec, M.; Wisniowski, R.; Siolek, M.; Narod, S.A.; Lubinski, J. Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers. Breast Cancer Res. Treat. 2008, 108(2), 289-296.
68. Wojciechowska-Lacka, A.; Markowska, J.; Skasko, E.; Kruczek, A.; Steffen, J. Frequent disease progression and early recurrence in patients with familial ovarian cancer primarily treated with paclitaxel and cis- or carboplatin (preliminary report). Eur. J. Gynaecol. Oncol. 2003, 24(1), 21-24.
69. Quinn, J.E.; James, C.R.; Stewart, G.E.; Mulligan, J.M.; White, P.; Chang, G.K. F.; Mullan, P.B.; Johnston, P.G.; Wilson, R.H.; Harkin, D.P. BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy. Clin. Cancer Res. 2007, 13(24), 7413-7420.
70. Lee, M.N.; Tseng, R.C.; Hsu, H.S.; Chen, J.Y.; Tzao, C.; Ho, W.L.; Wang, Y.C. Epigenetic inactivation of the chromosomal stability control genes BRCA1, BRCA2, and XRCC5 in non-small cell lung cancer. Clin. Cancer Res. 2007, 13(3), 832-838.
71. Taron, M.; Rosell, R.; Felip, E.; Mendez, P.; Souglakos, J.; Ronco, M.S.; Queralt, C.; Majo, J.; Sanchez, J.M.; Sanchez, J.J.; Maestre, J. BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Hum. Mol. Genet. 2004, 13(20), 2443-2449.
72. Wachters, F.M.; Wong, L.S. M.; Timens, W.; Kampinga, H.H.; Groen, H.J. M. ERCC1, hRad51, and BRCA1 protein expression in relation to tumour response and survival of stage III/IV NSCLC patients treated with chemotherapy. Lung Cancer 2005, 50(2), 211-219.
73. Wang, L.; Wei, J.; Qian, X.; Yin, H.; Zhao, Y.; Yu, L.; Wang, T.; Liu, B. ERCC1 and BRCA1 mRNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and/or docetaxel. BMC Cancer 2008, 8(1), 97.
74. Rosell, R.; Skrzypski, M.; Jassem, E.; Taron, M.; Bartolucci, R.; Sanchez, J.J.; Mendez, P.; Chaib, I.; Perez-Roca, L.; Szymanowska, A.; Rzyman, W.; Puma, F.; Kobierska-Gulida, G.; Farabi, R.; Jassem, J. BRCA1: A novel prognostic factor in resected non-small-cell lung cancer. PLoS ONE 2007, 2(11), e1129.
75. Reguart, N.; Cardona, A.F.; Carrasco, E.; Gomez, P.; Taron, M.; Rosell, R. BRCA1: a new genomic marker for non-small-cell lung cancer. Clin. Lung Cancer 2008, 9(6), 331-339.